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Background: Sleep disorders are very common in the community and are estimated to affect up to 45% of the
world’s population. Pharmacists are in a position to give advice and provide appropriate services to individuals who
are unable to easily access medical care. The purpose of this study is to develop an intervention to improve the
management of sleep disorders in the community. The aims are– (1) to evaluate the effectiveness of a community
pharmacy-based intervention in managing sleep disorders, (2) to evaluate the role of actigraph as an objective
measure in monitoring certain sleep disorders and (3) to evaluate the extended role of community pharmacists in
managing sleep disorders. This intervention is developed to monitor individuals undergoing treatment and
overcome the difficulties in validating self-reported feedback.
Method/design: This is a community-based intervention, prospective, controlled trial, with one intervention group
and one control group, comparing individuals receiving a structured intervention with those receiving usual care
for sleep-related disorders at community pharmacies.
Discussion: This study will demonstrate the utilisation and efficacy of community pharmacy-based intervention to
manage sleep disorders in the community, and will assess the possibility of implementing this intervention into the
community pharmacy workflow.
Trial registration: Australian New Zealand Clinical Trial Registry: ACTRN12612000825853
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Sleep disorders appear to be a global epidemic, affecting
up to 45% of the world’s population [1]. Sleep disorders
encompass problems with falling or staying asleep, wak-
ing up too early or too late, and problems with poor
sleep quality, all of which may cause significant impair-
ment of daytime functioning.
The community pharmacy is accessible and can provide
services to patients who may not regularly come into con-
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distribution, and reproduction in any mediumof health care [2]. Community pharmacy can therefore
offer primary assistance for sleep-related disorders to the
community. Even though specialist sleep clinics are avail-
able, they may not be accessible everywhere especially in
rural and remote areas. These specialist clinics tend to
focus very much on respiratory disorders of sleep and are
considered as tertiary centres which treat later stage or
more severe sleep disorders only. Community pharmacists
are already in a suitable position to initiate conversation,
discuss medicines, and provide ongoing follow-up [3] re-
lated to a range of health problems, and many interven-
tions have been implemented for other chronic health
problems such as asthma [4-8], diabetes [9-11] and hyper-
tension [12,13]. There are many similarities between these
chronic health problems and sleep disorders in terms
of early intervention, community-level management and
continuing care provision. This suggests that pharmacy-Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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cant role in effectively reducing the burden of these
disorders.
There are many types of sleep disorders, but by far the
most prevalent in adults are insomnia and obstructive
sleep apnoea (OSA) [14-16]. The current gold standard
treatments for diagnosed OSA and insomnia patients are
continuous positive airway pressure (CPAP) [17,18] and
cognitive behavioural therapy (CBTi) respectively [19,20].
However, due to varying results or personal preference
[21], many of these patients still present at the community
pharmacy seeking additional or alternative treatment op-
tions [22,23]. Pharmacists also assist many ‘walk-in’ indi-
viduals who often use the community pharmacy as a
primary contact to seek help for a variety of problems in-
cluding sleep-related disorders. Many of these individuals
have common or overlapping symptoms or simply present
with ‘poor sleep’, thus make it difficult for health profes-
sionals to accurately assess and/or treat.
Currently, in managing sleep-related disorders, commu-
nity pharmacists depend on self-report from patients or
on sleep diaries, if indicated. Monitoring sleep disorders is
difficult without appropriate tools, education or standard
measures. Determining the actual sleep problem and plan-
ning meaningful strategies can therefore be complicated
without objective measures. To date, in our knowledge,
most studies involving sleep disorders in community phar-
macies focused on screening tools [24-26] with very few
studies incorporating patient follow-up and monitoring by
community pharmacists [27].
This study will use a step-wise approach designed to
tackle ‘poor sleep’ in all individuals with disturbed sleep,
with referral procedures in place if the problem is not
resolved. We will investigate the potential extended role
of the pharmacists and the development of an interven-
tion to monitor individuals with poor sleep using a con-
venient and portable measuring device as an objective
measure to gain feedback on sleep. A wrist-actigraph
(SBV2 Readiband™) allows pharmacy staff to follow those
undergoing treatment by measuring the quality and
quantity of sleep, and to better characterise their sleep.
While monitoring treatment is difficult if self-reporting
is poor, the use of actigraphy can overcomes this chal-
lenge by providing objective, patient friendly and graph-
ical feedback that confirms certain sleep parameters and
validates the self-reported feedback. An individual acti-
graphy report can be used as the focus reference in pa-
tients’ consultations regarding sleep.
As a portable device, the actigraph can record move-
ment over extended periods of time, and has been used
extensively in the studies of sleep and circadian rhythm
[28-34]. Guidelines by the American Academy of Sleep
Medicine (AASM) signified that actigraphy is a very use-
ful method but it is not sufficient for all diagnoses.Clinical guidelines and research suggested that actigra-
phy is particularly useful in the evaluation of insomnia,
circadian rhythm sleep disorders (e.g. advance sleep-
phase syndrome (ASPS), delayed sleep-phase syndrome
(DSPS), jet lag and shift work sleep disorder), sleep re-
lated breathing disorders (e.g. sleep apnoea), determin-
ation of response to treatment and in an evaluation of
sleep patterns in special populations [28,29]. The acti-
graph can be used at home by patients without supervi-
sion from a trained sleep technician. Positive feedback
was received in a feasibility study to determine the possi-
bility and acceptability of actigraphy as a home-base
sleep measure. Participants admitted no disruptions to
daily tasks while wearing it [35].
This paper describes the research protocol of our
study, developed as a community pharmacy-based inter-
vention to improve the management of sleep disorders
in the community.
Research aims
The purpose of this study is to develop an intervention
to improve the management of sleep disorders in the
community. The aims are: (1) to evaluate the effective-
ness of a community pharmacy-based intervention in
managing sleep disorders, (2) to evaluate the role of acti-
graph as an objective measure in monitoring certain
sleep disorders and (3) to evaluate the extended role of
community pharmacists in managing sleep disorders.
Methods and design
Study design
This is a community-based intervention, prospective,
controlled trial, with one intervention group and one
control group (Figure 1).
Study setting
Four to five community pharmacies in the Brisbane
metropolitan area with similar demographic criteria and
physical locations will be recruited based on conveni-
ence sampling.
Ethics approval
This project has been approved by the School of Pharmacy
Ethics Committee, The University of Queensland (Refer-
ence number: 2012/04).
Pharmacies
Pharmacy eligibility criteria
Community pharmacies that meet the following criteria
are eligible to participate as a study site:
 Pharmacies that have high daily ‘walk-in customer’
turnover i.e. 100 to 300 customers per day for any
‘Pharmacist only medicine’, ‘Pharmacy medicine’,
‘Walk-in customer’ presents at
pharmacy with sleep-related
disorders or experiencing 
symptoms of sleep disorders.
‘Walk-in customer’ presents at
pharmacy with sleep-related
disorders or experiencing 
symptoms of sleep disorders.
Standard care Standard care
Discuss about the study Discuss about the study
Assessment for eligibility Assessment for eligibility
YES YESNO
Exclude 
from 
study
Recruitment                 
(intervention care)
Recruitment (usual care)
Follow-up / End of study
(by email/mail)
2 weeks
Follow-up 1
at community pharmacy
Follow-up 2 / End of study
at community pharmacy
1 week
1 week
Control PharmacyIntervention Pharmacy 
(Received a half-day training
session prior to study)
Figure 1 Study design (File attached).
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supplements.
Additional criteria for the ‘Intervention care group’
pharmacies:
 Agree to install a software application (Sleep
Consultant™ by Fatigue Science) which enables data
to be downloaded from the actigraph to generate an
individual sleep report for the participants.
 Have a private counselling area within the pharmacy
where one-to-one consultations with customers will
be separated from the common pharmacy counter.
 Able to follow-up participants for 2 weeks from
baseline.
Recruitment of pharmacies
Contact information of the pharmacies will be obtained
from the list of community pharmacies from publically
available lists. Community pharmacies which meet the
inclusion criteria will be invited to join the study by tele-
phone and informed about the project. If the pharmacistexpresses an interest, a research officer will arrange a
face-to-face discussion for further explanation of the
study and obtain consent. Upon agreement, the pharma-
cies will be assigned to either intervention or control
group, based on convenience sampling.Training for pharmacists and pharmacy assistants
This study will involve both pharmacists and pharmacy as-
sistants. One survey found that only 30% of direct sleep
product requests were handled entirely by pharmacists
and in a symptom based scenario, only 18% of requests
were handled by pharmacists [36]. Thus pharmacy assis-
tants will be included to reflect common practice and sup-
port the pharmacists.
Pharmacists and pharmacy assistants from the inter-
vention pharmacies will attend a half-day training course
provided by a sleep psychologist focusing on the use of
the actigraph and sleep diaries, sleep scale scores assess-
ment and questionnaires, and provide information on a
healthy lifestyle and sleep-related disorders. The acti-
graph user’s manual will be provided.
Table 1 Participant eligibility criteria
Eligibility criteria
Inclusion Exclusion
• Aged≥ 18 years old • Aged < 18 years old
• Attend a participating pharmacy
as a ‘walk-in customer’ seeking
help for sleep-related disorders or
having symptoms of sleep
disorders.
• Not able to speak, read and write
in English, or not fluent in English
and cannot arrange for a
translator themselves or a
translator is not available.
• Unable to complete the
screening (in the pharmacist’s
opinion).
• Refuse to give consent.
• Pregnant.
• Currently under treatment with
continuous positive airway
pressure (CPAP)
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Sample size
In similar population-based studies which correlate the re-
sults of actigraphy against other measures, i.e. polysomno-
graphy and/or sleep diaries, the number of participants
recruited varies, ranging from 30 to 450 participants
[37-39]. To our knowledge, there is no published research
relating to community pharmacy-based interventions uti-
lising actigraphy in sleep health management, therefore no
standard reference could be used to determine sample size
required for this study. In this study, sample size calcu-
lation is based on differences in sleep parameters (sleep
onset latency (SOL) and total sleep time (TST)) be-
tween actigraphy and sleep diaries [40,41]. Using Power
and Sample Size Calculation software version 3.0 2009
(Vanderbilt University), to demonstrate a 20% difference
in those sleep parameters between actigraphy versus
sleep diary, with 80% power sample and a p-value of
0.05, 25 participants are required per study group. To
allow for potential dropouts (approximately 10% over
2 weeks), a minimum of 55 participants will be recruited.
Recruitment of participants
Potential participants will be selected from walk-in cus-
tomers who present at the participating pharmacies
seeking help for sleep-related disorders or having symp-
toms of sleep problems. In both the intervention and
control groups, in addition to the usual discussion and
service about sleep health, the pharmacist or the phar-
macy staff will invite potential participants to join the
study. If they show an interest, further discussion will be
provided at a private area in the pharmacy prior to
obtaining consent. Those who agree to join the study,
will be assigned to either intervention or control group
participants, based on which pharmacy they attend.
Intervention participants - intervention care group (ICG)
At baseline, study eligibility (Table 1) will be checked
and inform consent will be obtained before the recruited
participants complete the ‘Initial Pharmacy Visit’ ques-
tionnaires. Sleep-hygiene advice will also be provided to
the participants. Due to the pragmatic nature of the
study, eligibility criteria are not restricted to specific
sleep disorders.
The actigraph is a useful device for monitoring sleep-
related disorders, but literature suggests that it should
be used in conjunction with other parameters, such as
sleep diaries [31,42] as both may complement each other
by providing objective and subjective data, respectively.
Therefore, participants will be provided with an inter-
vention package, which includes:
1. An actigraph (SBV2 Readiband™) to be worn 24-
hours a day for seven days before participants revisitthe pharmacy for their first follow-up, and then for a
further seven days after the first follow-up before
returning to the pharmacy for final assessment.
2. A sleep diary [43] to self-record 14 days of bedtime,
wake time, time to fall asleep, number of nocturnal
awakenings and total sleep time, plus information
related to sleep-hygiene, lifestyle and other factors
that may interrupt sleep.
3. Educational information about sleep disorders, sleep
health management, sleep hygiene and healthy
lifestyle to improve sleep (via access link to a
website: http://sleepproblemandyou.wordpress.com/
which is developed specifically for this study). The
web address will be provided to each participants.
One complete study duration for a participant in the
intervention group is two weeks with follow-ups at two
time points; week 1 (day 8) and week 2 (day 15). At both
time points, pharmacy staff will analyse the data down-
loaded from the actigraph using Sleep Consultant™ soft-
ware to generate an on-the-spot individualise report of
sleep/wake patterns and they will also assess the self-
report information from the sleep diary.Follow-up 1 The participants will receive sleep advice
and possible solutions focusing on behavioural strategies
such as sleep hygiene, change of lifestyle, daily alcohol
and caffeinated drinks consumption and activities before
going to sleep, based on data gained from both parame-
ters. Any requests for sleep medicine (‘Pharmacist only
medicine’ or ‘Pharmacy medicine’) will follow the phar-
macy’s standard practice. After this session, the partici-
pants will continue to wear the actigraph plus complete
the sleep diary for another seven days.
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second (post) individual sleep reports will be compared to
assess any particular improvement in their sleep condition
after receiving sleep advice and possible solution during
the first follow-up. Participants will also complete the ‘End
of Study’ questionnaires. In certain circumstances (see the
‘Protocol to refer participant to a general practitioner’ sub-
section), pharmacists can recommend a GP referral for
further examination.Protocol to refer participant to a general practitioner
(GP) at the end of study In these circumstances: (1) if
the sleep efficiency percentage (SE%) is below 85% at the
end of study (normal SE% for adult if measure using
actigraphy is 85% and above) [41,44], and (2) if analysis
of the data collected appears to indicate that he/she may
be at risk of having/developing sleep-related problems
and has reported symptoms such as:
 choking or suffocating during sleep
 stopping breathing when sleep
 snoring during sleep
 excessive daytime sleepiness
 difficulty falling asleep at night
 having problems waking up in the morning
 falling asleep too early at night
 waking up too early at night
 fatigue and having difficulty concentrating on daily
tasks
 experiencing unpleasant sensations with an urge to
move their limbs
Above symptoms may be indicative of another sleep
disorders, specifically OSA, narcolepsy, a circadian
rhythm disorder, restless legs syndromes or a primary
mood disorder.Control participants - usual care group (UCG)
The usual care group (UCG) participants will receive
standard or usual care for sleep disorders based on the
usual practice in the community pharmacy. Australian
community pharmacies usually follow the Pharmaceut-
ical Society of Australia’s recommended practice [45],
which includes supplying ‘Pharmacy medicine’, ‘Pharma-
cist only medicine’, complementary medicine or other
over-the-counter (OTC) medicines for sleep-related dis-
orders, if indicated. At baseline, follow the same protocol
as in the intervention group, study eligibility (Table 1)
will be checked and inform consent will be obtained be-
fore the participants complete the ‘Initial Pharmacy
Visit’ questionnaires. Baseline demographic and assess-
ments will be completed for comparisons with the ICG
participants. The UCG participants will be followed-upafter two weeks by the study researcher via email or mail
to complete the ‘End of Study’ questionnaires.
Study measurements and outcomes
Study measurements
Assessments will be conducted at three times points –
baseline, week 1 and week 2 (Table 2). At baseline upon
recruitment, participants will be assisted to complete the
self-administered ‘Initial Pharmacy Visit’ questionnaires,
comprise of:
 Demographic and lifestyle information, which
includes sleep environment, smoking, alcohol
consumption and caffeinated drinks intake, modified
from the validated ‘Pharmacy Tool for Assessment
of Sleep Health - POTASH’ [24].
 Health-related quality of life (HRQOL) assessment
using validated WHO-Five Well Being Index
(version 1998) [46,47].
 Sleep health assessment using a set of survey
instruments adapted from POTASH [24]: Epworth
Sleepiness Scale (ESS) [48,49], Insomnia Severity
Index (ISI) [50], Multivariate Apnea Prediction
Index (MAPI) [51] and International Restless Legs
Syndrome Study Group (IRLSSG) [52].
 Community pharmacy survey: 14 questions using a
5-point Likert-type scale from 1 (strongly disagree)
to 5 (strongly agree), and one open ended
question.
Follow-up after one week from baseline will be con-
ducted in the ICG only (Table 2). Assessment (pre) of
sleep parameters will be obtained from the actigraph and
sleep diary for these measures: (i) Sleep efficiency percent-
age (SE%), (ii) Total sleep time (TST) per 24-hour period
(hours/day), (iii) Number of nocturnal awakenings (NWAK),
and (iv) Sleep onset latency (SOL).
Follow-up at week 2 will be conducted to complete
the study in both groups (Table 2). Assessment (post) of
sleep parameters will be obtained from the actigraph
and sleep diary, as in previous follow-up. Participants
will also complete the ‘End of Study’ questionnaires,
comprise of:
 HRQOL assessment using validated WHO-Five Well
Being Index (version 1998).
 Sleep health assessment (consist of ESS, ISI, MAPI
and IRLSSG), adapted from POTASH [24].
 A close-out survey, consisting of: (i) questionnaire
on sleep-related lifestyle and behaviour changes
since completing the study, (ii) self-opinion of sleep
health after the study, and (iii) willingness and ability
to pay if such program is offered as a service by
community pharmacy.
3.
Table 2 Summary of measurements and study outcomes
Measurements Instruments Group T0 T1 T2 Outcome
Surveys/measuring tools
Socio-demographic and lifestyle Questionnaire ICG, UCG x 2˚
Health-related quality of life I,E WHO-5 Well-being index (1998) ICG, UCG x x 1˚
Sleep scale scores I,E ESS, ISI, MAPI, IRLSSG ICG, UCG x x 1˚
Community pharmacy survey I Questionnaire ICG, UCG x 2˚
Close-out survey E Questionnaire ICG, UCG x 1˚ 2˚
Sleep parameters assessment
SE% Actigraph only ICG x x 1˚
TST, NWAK, SOL Actigraph and sleep ICG x x 1˚
diary
Other factors that may interrupt sleep Sleep diary only ICG x x 1˚
Pharmacy survey
Close-out survey for pharmacy Questionnaire Pharmacists, pharmacy staff x 2˚
T0 = baseline, T1 = 1 week after baseline, T2 = 2 weeks after baseline.
ICG: intervention care group; UCG: usual care group.
ESS: Epworth Sleepiness Scale; ISI: Insomnia Severity Index; MAPI: Multivariate Apnea Prediction Index; IRLSSG: International Restless Legs Syndrome Study Group.
SE%: Percentage of sleep efficiency; TST: Total sleep time per-24 hour period; NWAK: Number of nocturnal awakenings; SOL: Sleep onset latency.
1˚: Primary outcome; 2˚: Secondary outcome.
I: ‘Initial Pharmacy Visit’ Questionnaires; E: ‘End of Study’ Questionnaires.
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macy staff will complete a self-administered question-
naire on the feasibility of the study, and opinions on the
management of sleep disorders after participating in the
study (Table 2).
Study outcomes
The primary outcomes (Table 2) of the study will be
evaluated based on these three objectives:
1. To evaluate a community pharmacy-based ‘model of
care’ to improve the management of sleep disorders
in the community, by comparing:2.a. Changes in HRQOL mean scores between and
within the intervention care group (ICG) and
usual care group (UCG) at baseline and week 2.
b. Changes in sleep scale mean scores – ESS, ISI,
MAPI and IRLSSG, between and within the
intervention care group (ICG) and usual care
group (UCG) at baseline and week 2.
c. Changes in sleep parameter mean scores – sleep
efficiency percentage (SE%), total sleep time
(TST), number of nocturnal awakenings (NWAK)
and sleep onset latency (SOL), between pre– and
post–actigraphy sleep report data in the
intervention care group (ICG).To evaluate the role of actigraph as an objective
sleep assessment instrument to monitor certain
sleep disorders, by comparing:a. Changes in sleep parameter mean scores –total
sleep time (TST), number of nocturnal awakenings
(NWAK) and sleep onset latency (SOL), between
actigraphy and sleep diary at week 1 and week 2 in
the intervention care group (ICG).To evaluate the extended role of community
pharmacists in managing sleep disorders in the
community, by evaluating:
a. Participants’ opinions of sleep health at the end of
the study.
b. Willingness and the amount able to pay if such
programme is provided as a service in the
community pharmacy.Secondary outcomes (Table 2) to be evaluated are:
1. Participants’ opinions of the community pharmacy
and opinions on the use of community pharmacy to
seek help for sleep-related disorders.
2. Comparison between groups in sleep-related lifestyle
and behaviours at week 2 follow-up.
3. Pharmacist and pharmacy staff opinions regarding
the feasibility of the study and the management of
sleep disorders in the community pharmacy after
participating in the study.
Data analysis
Data will be collected from the sleep report generated
from the Sleep Consultant™ software, sleep diary, and
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ters measurement, i.e. sleep efficiency percentage (SE%),
total sleep time (TST), sleep onset latency (SOL) and
number of nocturnal awakenings (NWAK) of a single
participant through either the sleep diary or actigraphy
will be averaged from all the data recorded during the 2-
week period (recorded as ‘pre’ (week 1) and ‘post’ (week
2) mean scores). There will be no discrimination be-
tween weekdays and weekend data. Sleep scale scores to
assess sleep health using ESS, ISI, MAPI and IRLSSG
survey recorded at baseline and week 2 will be averaged
to mean scores for analysis.
Data will be analysed using SPSS 20.0 for windows
[53]. This study will consider alpha level of 0.05 for all
statistical tests. Using descriptive, paired t-test and inde-
pendent t-test – demographic characteristics and sleep
scale scores between and within groups will be com-
pared. In the ICG, pairwise differences of sleep parame-
ters mean scores between actigraphy and sleep diary will
be calculated using independent t-test, and will be used
paired-t-test in comparing within group, for pre– and
post–mean scores (for normally distributed data). To de-
termine correlation between two variables, Pearson’s
correlation will be applied. Likert-type questions will be
analysed as descriptive analysis.Discussion
Sleep disorders are a concern worldwide and an emerging
public health problem [1,54,55], thus it requires a range of
strategies from public education through to clinical ser-
vices to manage it. Exploring and developing new inter-
ventions to improve the management of sleep disorders
within the primary healthcare system such as a commu-
nity pharmacy-based approach is crucial as health care
costs continue to increase [56]. Pharmacists are in a suit-
able position to provide an appropriate and vital step to
improve sleep health management [24-27]. To our know-
ledge, this is the first community pharmacy-based study
evaluating an intervention integrated into the community
pharmacy workflow, to enable pharmacists to improve the
management of sleep disorders.Abbreviations
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